Science Daily: Pharmacology News

APRIL 22, 2025

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions -- but there is always room for improvement. A new paper showcases the power of scalable protein engineering combined with machine learning to boost progress in the field of gene and cell therapy. In their study, authors developed a machine learning algorithm -- known as PAMmla -- that can predict the properties of about 64 million genome editing enzymes.

Engineering 168

Engineering Research Therapies 168

Covalent Modifiers

APRIL 25, 2025

Hayden A. Sharma, Michael Bielecki, Meredith A. Holm, Ty M. Thompson, Yue Yin, Jacob B. Cravatt, Timothy B. Ware, Alex Reed, Molhm Nassir, Tamara El-Hayek Ewing, Bruno Melillo, J. Fernando Bazan, Phil S. Baran, and Benjamin F. Cravatt Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c01944 Activity-based protein profiling (ABPP) of stereoisomerically defined sets of electrophilic compounds (stereoprobes) offers a versatile way to discover covalent ligands for proteins in native b

147

147

Drugs.com

APRIL 25, 2025

FRIDAY, April 25, 2025 Novavaxs COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company said Wednesday.The update sent Novavaxs stock up more than 21% in early trading. It also helped ease.

FDA Approval 343

FDA Approval Vaccine FDA Drugs 343

BioPharma Drive: Drug Pricing

APRIL 21, 2025

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug Wegovy two years after reporting initial Phase 3 results.

FDA Approval 350

FDA Approval FDA Regulations Drugs 350

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Science Daily: Pharmacology News

APRIL 21, 2025

New research links fatty, sugary diets to impaired brain function. The findings build on a growing body of evidence showing the negative impact of high-fat, high-sugar (HFHS) diets on cognitive ability, adding to their well-known physical effects.

Research 338

Research 338

Drugs.com

APRIL 25, 2025

FRIDAY, April 25, 2025 -- On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a pandemic influenza vaccine, according to a report from the.

Vaccine 291

Vaccine Government 291

BioPharma Drive: Drug Pricing

APRIL 25, 2025

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Marketing 262

Marketing Drugs 262

Science Daily: Pharmacology News

APRIL 24, 2025

Humans are better than current AI models at interpreting social interactions and understanding social dynamics in moving scenes. Researchers believe this is because AI neural networks were inspired by the infrastructure of the part of the brain that processes static images, which is different from the area of the brain that processes dynamic social scenes.

Research 297

Research 297

Covalent Modifiers

APRIL 20, 2025

Genhui Xiao, Yumeng Cui, Liangliang Zhou, Chuya Niu, Bing Wang, Jinglan Wang, Shaoyang Zhou, Miaomiao Pan, Chi Kin Chan, Yan Xia, Lan Xu, Yu Lu, Shawn Chen mLife , 2025 DOI: [link] The caseinolytic protease complex ClpP1P2 is crucial for protein homeostasis in mycobacteria and stress response and virulence of the pathogens. Its role as a potential drug target for combating tuberculosis (TB) has just begun to be substantiated in drug discovery research.

Small Molecule 147

Small Molecule Drugs Research 147

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drugs.com

APRIL 21, 2025

MONDAY, April 21, 2025 -- Colonoscopy for younger adults. Chest CT scans for lung cancer. Statin meds to lower cholesterol. Screening for drug addiction.More than 150 million Americans might lose no-cost access to these and other preventive care.

Drugs 286

Drugs 286

BioPharma Drive: Drug Pricing

APRIL 22, 2025

The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S.

Production 251

Production Drugs 251

Science Daily: Pharmacology News

APRIL 24, 2025

Mind blanking is a common experience with a wide variety of definitions ranging from feeling 'drowsy' to 'a complete absence of conscious awareness.' Neuroscientists and philosophers compile what we know about mind blanking, including insights from their own work observing people's brain activity.

292

292

Chemical Biology and Drug Design

APRIL 25, 2025

Quercetin is the core component of Hedyotis diffusa against breast cancer (BRCA). CDK1, BIRC5, and HSP90AA1 play key roles in the anti-BRCA effect of Hedyotis diffusa. ABSTRACT Hedyotis diffusa , a famous Traditional Chinese Medicine (TCM), has been extensively used clinically for thousands of years. Although the therapeutic effect of Hedyotis diffusa on tumors has attracted wide attention, components, and mechanisms against breast cancer (BRCA) have not been fully understood.

Treatment 100

Treatment Research 100

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drugs.com

APRIL 21, 2025

MONDAY, April 21, 2025 The U.S. Centers for Disease Control and Prevention (CDC) has canceled its plans to help Texas schools stop the rapid spread of measles. The decision came after some CDC staff involved in this years outbreak response were t.

Disease 277

Disease 277

BioPharma Drive: Drug Pricing

APRIL 24, 2025

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

243

243

Science Daily: Pharmacology News

APRIL 23, 2025

An international team has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin. Scientists report that exposure to colibactin in early childhood imprints a distinct genetic signature on the DNA of colon cells -- one that may increase the risk of developing colorectal cancer before the age of 50.

DNA 291

DNA International 291

Collaborative Drug

APRIL 25, 2025

CDD Update March #2 2025 Full Atom Layout of Macromolecules New Dataset for AI Similarity Searching Import Inventory Locations by Unique Box Names:

238

238

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drugs.com

APRIL 24, 2025

THURSDAY, April 24, 2025 Patients who legitimately need opioid painkillers are finding it more difficult to get the meds they need, due to guardrails established in response to the U.S. opioid crisis, a new study says.Doctors who treat patients i.

Doctors 264

Doctors 264

keypoint

APRIL 22, 2025

Keystone Symposia was founded on the idea of bringing academic and industry scientists together to accelerate translational advances that cannot be achieved without their combined expertise and resources. As such, we have a long history of partnership with industry leaders with the shared goal of integrating basic science discovery and innovation into drug development efforts to yield novel and improved targeted treatment strategies.

Drug Development 96

Drug Development Science Treatment Drugs 96

Science Daily: Pharmacology News

APRIL 24, 2025

'Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

Regulations 288

Regulations Research 288

BioPharma Drive: Drug Pricing

APRIL 24, 2025

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene beforehand with a targeted medication.

Disease 179

Disease 179

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drugs.com

APRIL 23, 2025

WEDNESDAY, April 23, 2025 Microplastics could be contributing to clogged arteries, increasing peoples risk of heart attack or stroke, a new study says.Fatty plaques in neck arteries can contain more than 50 times as much microplastics as are fou.

265

265

FDA Law Blog: Drug Discovery

APRIL 21, 2025

By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a

FDA 64

FDA Drug Development Drugs International 64

Science Daily: Pharmacology News

APRIL 24, 2025

In a landmark clinical trial people at risk for Alzheimer's who exercised at low or moderate-high intensity showed less cognitive decline when compared to those receiving usual care.

Clinical Trials 287

Clinical Trials Trials 287

BioPharma Drive: Drug Pricing

APRIL 25, 2025

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

Therapies 177

Therapies Treatment 177

Drugs.com

APRIL 23, 2025

WEDNESDAY, April 23, 2025 -- Overuse of antibiotics might increase kids risk of developing asthma and allergies, by disrupting their gut bacteria during a crucial stage of child development, a new study says.Exposure to antibiotics prior to age 2 i.

262

262

New Drug Approvals

APRIL 25, 2025

Inavolisib WeightAverage: 407.378 Monoisotopic: 407.140510438 Chemical FormulaC 18 H 19 F 2 N 5 O 4 GDC-0077 CAS 2060571-02-8 GDC0077 RG6114 WHO 11204 GDC 0077 GDC-0077 RG-6114 RG6114 RO-7113755 RO7113755 FDA APPROVED, 10/10/2024, Itovebi , To treat locally advanced or metastatic breast cancer Drug Trials Snapshot (2 S )-2-[[2-[(4 S )-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazoli

FDA 58

FDA FDA Approval Therapies Trials 58

Science Daily: Pharmacology News

APRIL 25, 2025

A new study provides new evidence that sensory stimulation of a gamma-frequency brain rhythm may promote broad-based restorative neurological health response.

284

284

BioPharma Drive: Drug Pricing

APRIL 22, 2025

Henry Gosebruch is now chief executive of the spinout, which has roughly $2.5 billion and plans to use dealmaking to build a research pipeline targeting cancer, viruses and the immune system.

Virus 169

Virus Research 169